942144-14-1

Basic information

• Product Name: 3-Oxazolidinecarboxylic acid, 4-[(2R)-2-[[[(1,1-diMethylethyl)diMethylsilyl]oxy]Methyl]-4-penten-1-yl]-2,2-diMethyl-, 1,1-diMethylethyl ester, (4S)-
• Synonyms: 3-Oxazolidinecarboxylic acid, 4-[(2R)-2-[[[(1,1-diMethylethyl)diMethylsilyl]oxy]Methyl]-4-penten-1-yl]-2,2-diMethyl-, 1,1-diMethylethyl ester, (4S)-;(S)-tert-Butyl 4-((R)-2-(((tert-butyldimethylsilyl)oxy)methyl)pent-4-en-1-yl)-2,2-dimethyloxazolidine-3-carboxylate
• CAS NO: 942144-14-1
• Molecular Formula: C₂₂H₄₃NO₄Si
• Molecular Weight: 413.66662
• Mol File: 942144-14-1.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-Oxazolidinecarboxylic acid, 4-[(2R)-2-[[[(1,1-diMethylethyl)diMethylsilyl]oxy]Methyl]-4-penten-1-yl]-2,2-diMethyl-, 1,1-diMethylethyl ester, (4S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Oxazolidinecarboxylic acid, 4-[(2R)-2-[[[(1,1-diMethylethyl)diMethylsilyl]oxy]Methyl]-4-penten-1-yl]-2,2-diMethyl-, 1,1-diMethylethyl ester, (4S)-(942144-14-1)
• EPA Substance Registry System: 3-Oxazolidinecarboxylic acid, 4-[(2R)-2-[[[(1,1-diMethylethyl)diMethylsilyl]oxy]Methyl]-4-penten-1-yl]-2,2-diMethyl-, 1,1-diMethylethyl ester, (4S)-(942144-14-1)

Safety Data

• Hazardous Substances Data: 942144-14-1(Hazardous Substances Data)

Upstream product

• 942144-13-0 (S)-tert-butyl 4-((R)-2-(hydroxymethyl)pent-4-enyl)-2,2-dimethyloxazolidine-3-carboxylate 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 942144-12-9 tert-butyl (2S,4R)-1-hydroxy-4-(hydroxymethyl)hept-6-en-2-ylcarbamate 
• 144978-35-8 (S)-ethyl N-tert-butoxycarbonylpyroglutamate 
• 153080-81-0 (2S,4R)-1-tert-butyl 4-allyl-2-ethoxycarbonyl-5-oxopyrrolidine-1-carboxylate 

Downstream Products

• 942144-35-6 (S)-tert-butyl 4-((R)-2-((tert-butyldimethylsilyloxy)methyl)-5-hydroxypentyl)-2,2-dimethyloxazolidine-3-carboxylate 
• 942145-39-3 methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(methylamino)-3-((R)-tetrahydro-2H-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate trifluoroacetate 
• 1013937-63-7 methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-2-(methylamino)-3-((R)-tetrahydro-2H-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate trifluoroacetate 
• 942144-36-7 (S)-tert-butyl 4-((R)-2-((tert-butyldimethylsilyloxy)methyl)-5-(methylsulfonyloxy)pentyl)-2,2-dimethyloxazolidine-3-carboxylate 
• 942144-34-5 (S)-tert-butyl 2,2-dimethyl-4-(((R)-tetrahydro-2H-pyran-3-yl)methyl)oxazolidine-3-carboxylate 
• 942144-43-6 tert-butyl (S)-1-hydroxy-3-((R)-tetrahydro-2H-pyran-3-yl)propan-2-ylcarbamate 
• 942145-23-5 (S)-2-(tert-butoxycarbonylamino)-3-((R)-tetrahydro-2H-pyran-3-yl)propyl 4-methylbenzenesulfonate 
• 942145-24-6 tert-butyl (S)-1-azido-3-((R)-tetrahydro-2H-pyran-3-yl)propan-2-ylcarbamate 
• 942145-26-8 tert-butyl (S)-1-azido-3-((R)-tetrahydro-2H-pyran-3-yl)propan-2-yl(methyl)carbamate 
• 942145-27-9 tert-butyl (S)-1-amino-3-((R)-tetrahydro-2H-pyran-3-yl)propan-2-yl(methyl)carbamate 
• 1093864-75-5 methyl {2-[((R)-(3-chlorophenyl){3-[({(2S)-2-(methylamino)-3-[(3R)-tetrahydro-2H-pyran-3-yl]propyl}amino)carbonyl]phenyl}methyl)oxy]ethyl}carbamate 
• 1093864-97-1 methyl 2-((S)-(3-chloro-5-fluorophenyl)(3-((S)-2-(methylamino)-3-((R)-tetrahydro-2H-pyran-3-yl)propylcarbamoyl)phenyl)methoxy)ethylcarbamate 
• 1093864-96-0 methyl 2-((R)-(3-chloro-5-fluorophenyl)(3-((S)-2-(methylamino)-3-((R)-tetrahydro-2H-pyran-3-yl)propylcarbamoyl)phenyl)methoxy)ethylcarbamate 
• 1093865-51-0 [2-{3-[((S)-2-methoxycarbonylamino-ethoxy)-phenyl-methyl]-benzoylamino}-1-((R)-tetrahydro-pyran-3-ylmethyl)-ethyl]-methyl-carbamic acid tert-butyl ester 

Relevant articles and documents

Discovery of VTP-27999, an alkyl amine renin inhibitor with potential for clinical utility

Structure guided optimization of a series of nonpeptidic alkyl amine renin inhibitors allowed the rational incorporation of additional polar functionality. Replacement of the cyclohexylmethyl group occupying the S1 pocket with a (R)-(tetrahydropyran-3-yl)

RENIN INHIBITORS

Described are compounds that bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compounds described herein in ameliorating or treating aspartic protease related disorders in a subject in need thereof.